Camurus AB (publ) (STO:CAMX)
649.00
-6.50 (-0.99%)
At close: Oct 23, 2025
Camurus AB Revenue
Camurus AB had revenue of 675.50M SEK in the quarter ending June 30, 2025, with 51.84% growth. This brings the company's revenue in the last twelve months to 2.27B, up 42.25% year-over-year. In the year 2024, Camurus AB had annual revenue of 1.87B with 8.78% growth.
Revenue (ttm)
2.27B
Revenue Growth
+42.25%
P/S Ratio
17.07
Revenue / Employee
8.49M
Employees
256
Market Cap
38.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.22B |
| Elekta AB | 17.84B |
| Asker Healthcare Group AB | 15.88B |
| AddLife AB | 10.44B |
| Nolato AB | 9.63B |
| Vitrolife AB | 3.54B |
Camurus AB News
- 4 months ago - Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients - PRNewsWire
- 5 months ago - Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins - PRNewsWire
- 6 months ago - CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU - PRNewsWire
- 1 year ago - Camurus AB (CAMRF) Q3 2024 Earnings Call Highlights: Record Profit and Revenue Growth Amid ... - GuruFocus
- 1 year ago - Q3 2024 Camurus AB Earnings Call Transcript - GuruFocus
- 1 year ago - US FDA declines to approve Camurus' rare hormone disorder drug - Reuters
- 1 year ago - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl - PRNewsWire